Literature DB >> 22116797

The effects of a "new" walking aid on exercise performance in patients with COPD: a randomized crossover trial.

Anouk W Vaes1, Janneke Annegarn2, Kenneth Meijer2, Martijn W J Cuijpers3, Frits M E Franssen3, Jozé Wiechert4, Emiel F M Wouters5, Martijn A Spruit3.   

Abstract

BACKGROUND: Generally, the use of a rollator improves mobility in patients with COPD. Nevertheless, not all patients benefit from its use, and many patients feel embarrassed about using it. Therefore, other walking aids are worthwhile to consider. We compared the direct effects of a "new" ambulation aid (a modern draisine) with the effects of a rollator on 6-min walk distance (6MWD) in patients with COPD.
METHODS: Twenty-one patients with COPD performed two 6-min walk tests (6MWTs) during prerehabilitation assessment (best 6MWD: 369 ± 88 m). Additionally, two extra 6MWTs were performed on two consecutive days in random order: one time with a rollator and one time with a modern draisine. Walking pattern (n = 21) was determined using an accelerometer, and metabolic requirements (n = 10) were assessed using a mobile oxycon.
RESULTS: Walking with the modern draisine resulted in a higher 6MWD compared with walking with the rollator (466 ± 189 m vs 383 ± 85 m). Moreover, patients had fewer strides (245 ± 61 vs 300 ± 49) and a greater stride length (1.89 ± 0.73 m vs 1.27 ± 0.14 m) using the modern draisine compared with the rollator (all P ≤ .001). Oxygen uptake, ventilation, heart rate, oxygen saturation, and Borg symptom scores were comparable between both walking aids. Ten percent of the patients felt embarrassed using the modern draisine compared with 19% for the rollator, and a significantly smaller proportion of patients would use the modern draisine in daily life.
CONCLUSIONS: The mean difference in 6MWD between a modern draisine and a rollator seems clinically relevant, with the same metabolic requirements and symptom Borg scores. Therefore, this "new" ambulation aid could be a good alternative to the rollator to improve functional exercise performance in patients with COPD. TRIAL REGISTRY: The Netherlands National Trial Registry; No.: NTR1542; URL: www.trialregister.nl.

Entities:  

Mesh:

Year:  2011        PMID: 22116797     DOI: 10.1378/chest.11-1076

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Validation of the oxycon mobile metabolic system in healthy subjects.

Authors:  Marco A Akkermans; Maurice J H Sillen; Emiel F M Wouters; Martijn A Spruit
Journal:  J Sports Sci Med       Date:  2012-03-01       Impact factor: 2.988

Review 2.  COPD and exercise: does it make a difference?

Authors:  Martijn A Spruit; Chris Burtin; Patrick De Boever; Daniël Langer; Ioannis Vogiatzis; Emiel F M Wouters; Frits M E Franssen
Journal:  Breathe (Sheff)       Date:  2016-06

Review 3.  Technologies for the Instrumental Evaluation of Physical Function in Persons Affected by Chronic Obstructive Pulmonary Disease: A Systematic Review.

Authors:  Alberto Zucchelli; Simone Pancera; Luca Nicola Cesare Bianchi; Alessandra Marengoni; Nicola Francesco Lopomo
Journal:  Sensors (Basel)       Date:  2022-09-01       Impact factor: 3.847

4.  How to carry out a field walking test in chronic respiratory disease.

Authors:  Anne E Holland; Martijn A Spruit; Sally J Singh
Journal:  Breathe (Sheff)       Date:  2015-06

5.  Accompanied versus unaccompanied walking for continuous oxygen saturation measurement during 6-min walk test in COPD: a randomised crossover study.

Authors:  Thomas F Riegler; Anja Frei; Sarah R Haile; Thomas Radtke
Journal:  ERJ Open Res       Date:  2021-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.